Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
Date:2/5/2008

SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and year ended December 31, 2007. For the three months ended December 31, 2007, the Company reported a net loss of $128.0 million or $3.35 loss per share compared to a net loss of $14.7 million or $0.39 loss per share for the same period last year. For the year ended December 31, 2007, the Company had a net loss of $207.3 million, or $5.45 loss per share compared with a net loss of $107.2 million, or $2.84 loss per share in 2006. The increase in net loss is primarily the result of a one-time non-cash impairment charge of $94.0 million related to the write-off of the indiplon prepaid royalty during the fourth quarter of 2007. Additionally, the Company incurred a $6.9 million charge related to a severance program enacted in December 2007.

Revenues for the fourth quarter of 2007 were $0.5 million compared with $9.4 million for the same period last year. The Company recognized $0.5 million in license fee revenues during the fourth quarter of 2007 related to the licensing of the Japanese rights for indiplon to Dainippon Sumitomo Pharma Co. Ltd. (DSP). During the fourth quarter of 2006, the Company recognized license fee revenues arising from the Pfizer, Inc. (Pfizer) collaboration of $0.7 million. Additionally, the Company recognized milestones related to CRF drug candidate development under the GlaxoSmithKline (GSK) agreement of $8.0 million for the fourth quarter of 2006.

Revenues for the year ended December 31, 2007, were $1.2 million, compared with $39.2 million for 2006. The decrease in revenues for the year ended December 31, 2007 is primarily due to the cancellation of our col
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...
(Date:5/23/2013)... , May 23, 2013  Spring Bank Pharmaceuticals, ... treatment of viral infections, today announced that it has ... 9200, its investigational, once daily, oral therapy for the ... healthy, HCV-infected patients and is designed to assess both ... 9200 is a first-in-class drug for the treatment of ...
(Date:5/23/2013)... 2013   Direct to implant, or "one ... appropriate option for many women with BRCA (BReast ... breast cancer risk, or with breast cancer. Traditionally, ... a second surgery to insert permanent implants, but ... as mastectomy can be a medically and cosmetically ...
Breaking Medicine Technology:First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3
... , , , , , , ... MIVI-TRUST Phase III Program With Microplasmin Recruits a Total of Over,640 ... (Euronext Brussels: THR), a biopharmaceutical company,focused on the discovery and development ... that it has completed,the enrolment of the second Phase III trial ...
... , NORCROSS, Ga., Dec. 15 Immucor, Inc. (Nasdaq: ... to the blood transfusion industry, today announced that it will ... 6, 2010 after the market close. The Company will host ... a.m. (Eastern Time) to discuss the results. , ...
Cached Medicine Technology:ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4
(Date:5/23/2013)... A medical malpractice case which was filed ... by Lori Mandel, an office manager in her 50’s, ... Ms. Mandel sought the medical expertise of an ... that affected the quality of her life and her ... that her doctor rendered conservative treatment for 2 years, ...
(Date:5/23/2013)... International Science Consortium, Ltd., issued the following statement ... 2013: , Reform of chemical safety legislation will ... , Ensuring the safety and appropriate use ... the EPA,s Toxic Substances Control Act is a ... vision for transforming toxicity testing "from a system ...
(Date:5/23/2013)... in imaging of brain activity developed by Jean ... and his colleagues lead to improved treatment of ... electroencephalogram (EEG) and functional magnetic resonance imaging (fMRI) ... generating epileptic seizures, giving neurosurgeons a better understanding ... These results were presented at the 2013 ...
(Date:5/23/2013)... Bronson Gray HealthDay Reporter , , WEDNESDAY, May 22 ... device used to save an infant born with a serious ... marriage of bioengineering and surgery. A report in the ... the situation that sparked the innovation. At first, the ... began to have difficulty breathing and eating when he was ...
(Date:5/23/2013)... According to a new market report "Service Delivery ... Management (SDM); Telecom Application Server; Service Creation Environment; Orchestration ... published by MarketsandMarkets, the SDP Market is expected to ... 9.15% from 2013 to 2018. , Browse:, ... 84 Figures , 189 Pages and an ...
Breaking Medicine News(10 mins):Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 2Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 3Health News:New imaging techniques used to help patients suffering from epilepsy 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 3Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3
... , ENGLEWOOD, Colo., Aug. 10 Baxa, ... and administration of fluid medications, announces the launch of a ... and medication safety practices. The Culture of Safety Page, ... share experiences, insights and ideas for improving their profession and ...
... Aug. 10 /PRNewswire-Asia/ -- China Medicine Corporation,(OTC Bulletin ... leading,developer and distributor of prescription and over the ... supplements, and,medical devices and medical formulations, today announced ... a.m. Eastern Time on Thursday, August 13, 2009, ...
... , SAN FRANCISCO, Aug. 10 ... Mark Gastineau to senior vice president and chief executive of ... Unit (ISGBU). Gastineau joined Blue Shield in 2006 as ... underwriting and compliance areas in developing strategies to increase membership ...
... ... and school administrators will help U.S. schools meet growing needs of students with autism ... ... Society announced the publication of professional competencies for teaching students with autism spectrum disorders ...
... , , NEW YORK, Aug. 10 ... letter of intent to form ZiRx Therapeutics, Ltd., a joint venture that ... cell proteins with drugs that potentially block or stop the spread of ... to broad spectrum antiviral drugs as well as drugs that are less ...
... YORK, Aug. 10 In an unprecedented meeting at the UN, ... and currently an opposition leader and human rights protagonist for Iran, ... violations of human rights by the regime in Iran. , ... Secretary General for his June 22 statement of urgent concern over ...
Cached Medicine News:Health News:Baxa Corporation Launches 'Culture of Safety' Facebook Page 2Health News:Baxa Corporation Launches 'Culture of Safety' Facebook Page 3Health News:China Medicine Announces Conference Call to Discuss Second Quarter 2009 Results 2Health News:Mark Gastineau Named Senior Vice President of Individual, Small Group, and Government Business Unit at Blue Shield of California 2Health News:New National Professional Competencies for Teachers of Autism Released by Leaders in the Field 2Health News:New National Professional Competencies for Teachers of Autism Released by Leaders in the Field 3Health News:Rx for Africa, Inc. and Zirus, Inc. Create Joint Venture, ZiRx Therapeutics, Ltd. 2Health News:Rx for Africa, Inc. and Zirus, Inc. Create Joint Venture, ZiRx Therapeutics, Ltd. 3Health News:Former UN Human Rights Rapporteur Offers 7 Points of Action on Iran to the UN Secretary General 2
...
...
The AGC Revision Knee, extends the AGC Family to include implants for severe primary knees or revision. Provides rotational freedom of +/- 2 and varus/valgus freedom of +/- 1.5....
The Performance Knee System is a wide and easy to use system that offers enough options to cover any indication for primary and revision knee surgery, and all this with extensive intraoperative flexi...
Medicine Products: